Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
Executive Summary
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.
You may also be interested in...
Cell And Gene Therapy Companies Fear More Market Delays From EU’s Single Review Plans
Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.
European Countries Flag Four Medicines For Joint HTA Evaluation
Drugs for treating Duchenne muscular dystrophy and amyotrophic lateral sclerosis are among the products that the European cross-country coalition BeNeLuxA thinks would be suitable for a joint health technology evaluation.
Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut
Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.